A Study of the Gene Therapy CGF166 in Patients with Severe-to-Profound Hearing Loss

A three-part, multicenter, open label, single dose study of the gene therapy CGF166 in patients with severe-to-profound hearing loss. CGF166 is recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA. The purpose of the study is to evaluate the safety, tolerability, and the potential ability of CGF166 delivered through intra-labyrinthine infusion to improve hearing and vestibular function.

This clinical trial is closed for enrollment.

To inquire about participation, please contact:

Jessica Campbell

Clinical Coordinator



Principal Investigator:
Lawrence R. Lustig, MD